Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RILUZOLE vs RISANKIZUMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RILUZOLE vs RISANKIZUMAB: Safety Overview

Metric RILUZOLE RISANKIZUMAB
Total FAERS Reports 1,437 2,642
Deaths Reported 342 41
Death Rate 23.8% 1.6%
Hospitalizations 264 439
Average Patient Age 63.5 yrs 52.1 yrs
% Female Patients 47.5% 51.3%
FDA Approval Date Aug 22, 2024 N/A
Manufacturer EDW PHARMA AbbVie Inc.
Route ORAL SUBCUTANEOUS
Marketing Status Discontinued N/A